Skip Navigation


Carcinogenesis Advance Access originally published online on January 3, 2008
Carcinogenesis 2008 29(3):600-609; doi:10.1093/carcin/bgm264
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
29/3/600    most recent
bgm264v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Tiwari, M.
Right arrow Articles by Godbole, M. M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tiwari, M.
Right arrow Articles by Godbole, M. M.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Inhibition of N-(4-hydroxyphenyl)retinamide-induced autophagy at a lower dose enhances cell death in malignant glioma cells

Meenakshi Tiwari, Virendra Kumar Bajpai2, Amogh Anant Sahasrabuddhe2, Ashok Kumar, Rohit Anthony Sinha, Sanjay Behari1 and Madan Madhav Godbole*

Department of Endocrinology
1 Department of Neurosurgery, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Raebareli Road, Lucknow 226 014, India
2 Electron Microscopy Unit, Central Drug Research Institute, Mahatma Gandhi Marg, Lucknow 226 001, India

* To whom correspondence should be addressed. Tel: +91 522 2668700 ext. 2368; Fax: +91 522 2668017; Email: madangodbole{at}yahoo.co.in

The question whether chemotherapy-induced autophagy is causative to the demise of the cells or a part of the survival mechanism activated during cellular distress is unclear. Others and we have previously demonstrated apoptosis-inducing capacity of N-(4-hydroxyphenyl)retinamide (4-HPR) in malignant glioma cells. We provide evidences of 4-HPR-induced autophagy at a lower concentration (5 µM). Suboptimal dose of 4-HPR treatment of malignant glioma cell lines increased G2/M arrest, whereas cell accumulated in S phase at a higher concentration. 4-HPR-induced autophagy was associated with acidic vacuole [acidic vesicular organelle (AVO)] formation and recruitment of microtubule-associated protein light chain 3 (LC3). At a higher concentration of 10 µM of 4-HPR, glioma cells undergoing apoptosis manifested autophagic features indicated by autophagosome formation, AVO development and LC3 localization. Autophagy inhibition at an early stage by 3-methyl adenine inhibited the AVO formation and LC3 localization with an enhancement in cell death. Bafilomycin A1, a specific inhibitor of vacuolar type Hþ-ATPase also prevented AVO formation without effecting LC-3 localization pattern and also enhanced the extent of 4-HPR-induced cell death. 4-HPR activated c-jun and P38MAPK at both 5 and 10 µM concentrations, whereas increased activation of extracellular signal-regulated kinase 1/2 and NF-kappaB was seen only at lower dose. Inhibiting phosphoinositide 3-kinase and mitogen-activated protein kinases pathways modulated 4-HPR-induced cell death. This is the first report that provides evidences that besides apoptosis induction 4-HPR can also induce autophagy. These results indicate that 4-HPR-induced autophagy in glioma cell may provide survival advantage and inhibition of autophagy may enhance the cytotoxicity to 4-HPR.

Abbreviations: AO, acridine orange; AVO, acidic vesicular organelle; Baf-A1, bafilomycin A1; CMFDA, 5-chloromethylfluoresceine diacetate; DCF-DA, 2',7'-dichlorofluorescine diacetate; DMSO, dimethyl sulfoxide; ERK, extracellular signal-regulated kinase; 4-HPR, N-(4-hydroxyphenyl)retinamide; JC-1, 5,5',6,6'-tetrachlo-1-1',3,3'tetraethylbenzimidazolylcarbocyanine iodide; JNK, c-jun N-terminal kinase; LC3, light chain 3; LTR, Lysotracker red; 3-MA, 3-methyl adenine; MAPK, mitogen-activated protein kinase; NF-{kappa}B, NF-kappaB; PBS, phosphate-buffered saline; PI, propidium iodide; PI3K, phosphoinositide 3-kinase; ROS, reactive oxygen species

Received May 25, 2007; revised October 30, 2007; accepted October 30, 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.